| Name: |
SALBUTAMOL (VentolinR) |
| Classification: |
beta2 agonist, bronchodilator |
| Dose: |
- Inhalation:
- 0.25 to 0.5 mg (up to 1 mg) q 4 - 6 h
- Infusion:
- 5 mcg/min, increase by 5 mcg/min to a maximum of 20 mcg/min
|
| Administration: |
IV Infusion:
5 mg/500 mL dextrose 5% or sodium chloride 0.9%
dextrose containing solutions may be inappropriate for patients with diabetes because of salbutamol induced exaggerated hyperglycemia
|
| Adverse Effects: |
more common with parenteral therapy than inhalational therapy
- with inhalation:
- headache
- nervousness, tremor
- tachycardias
- with intravenous therapy:
- hypertension or hypotension
- hyperglycemia
- hypokalemia
- palpitations
- arrhythmias
|
| Caution: |
- in patients with cardiovascular disorders, hyperthyroidism and diabetes
|
| Drug Interactions: |
- salbutamol + sympathomimetics = exacerbation of cardiovascular effects
- salbutamol + beta blockers = mutual antagonism of therapeutic effect
- salbutamol + general anaesthetics = decreased BP, increased HR
|
| Monitoring Therapy: |
- Efficacy:
- breath sounds
- respiratory rate
- ventilatory pressures
- blood gases
- Adverse effects:
- continuous heart rate and rhythm
- blood pressure
- serum glucose
- serum potassium
|
| CCTC Protocol: |
- May be administered IV infusion in Adult Critical Care provided that the first dose is given by an MD
- Must be administered via Central Venous Line
- Continuous infusions must be administered by infusion device and the pump library must be enabled
- Patient requires the placement of an arterial line for continuous blood pressure monitoring
- Patient requires full mechanical ventilation with continuous End Tidal CO2 monitoring
|
